Literature DB >> 34138521

Hepatocellular carcinoma as a complication of Niemann-Pick disease type C1.

Jorge L Rodriguez-Gil1,2, Simona E Bianconi3, Nicole Farhat3, David E Kleiner4, Marie Nelson5, Forbes D Porter3.   

Abstract

Niemann-Pick disease type C (NPC) is a rare and fatal lysosomal storage disorder characterized by neurodegeneration and hepatic involvement. Mutations in either NPC1 or NPC2, two genes encoding lysosomal proteins, lead to an intracellular accumulation of unesterified cholesterol and sphingolipids in late endosomes/lysosomes. Early cholestatic disease is considered a hallmark of patients with early disease onset. This can potentially result in liver failure shortly after birth or subclinical hepatic inflammation. Previous reports suggest an association between NPC and hepatocellular carcinoma, a cancer that is rare during childhood. We present a 12-year-old male with a known diagnosis of NPC1 disease who was found to have a stage III hepatocellular carcinoma, underwent surgical resection with adjuvant chemotherapy, and subsequently died from metastatic disease. This report provides evidence of an increased risk of hepatocellular carcinoma in NPC patients, suggesting a need for screening in this patient population.
© 2021 Wiley Periodicals LLC. This article has been contributed to by US Government employees and their work is in the public domain in the USA.

Entities:  

Keywords:  NPC1; Niemann-Pick disease type C; hepatocellular carcinoma

Mesh:

Substances:

Year:  2021        PMID: 34138521      PMCID: PMC8446311          DOI: 10.1002/ajmg.a.62382

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.578


  45 in total

Review 1.  Liver disease in infancy: a 20 year perspective.

Authors:  G Mieli-Vergani; E R Howard; A P Mowat
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 2.  Hepatocellular carcinoma in children.

Authors:  Deirdre Kelly; Khalid Sharif; Rachel M Brown; Bruce Morland
Journal:  Clin Liver Dis       Date:  2015-02-28       Impact factor: 6.126

Review 3.  The adult form of Niemann-Pick disease type C.

Authors:  Mathieu Sévin; Gaëtan Lesca; Nicole Baumann; Gilles Millat; Olivier Lyon-Caen; Marie T Vanier; Frédéric Sedel
Journal:  Brain       Date:  2006-09-26       Impact factor: 13.501

4.  Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease.

Authors:  D A Kelly; B Portmann; A P Mowat; S Sherlock; B D Lake
Journal:  J Pediatr       Date:  1993-08       Impact factor: 4.406

Review 5.  Niemann-Pick disease type C.

Authors:  Marie T Vanier
Journal:  Orphanet J Rare Dis       Date:  2010-06-03       Impact factor: 4.123

6.  Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update.

Authors:  Marc C Patterson; Christian J Hendriksz; Mark Walterfang; Frederic Sedel; Marie T Vanier; Frits Wijburg
Journal:  Mol Genet Metab       Date:  2012-05-08       Impact factor: 4.797

7.  Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.

Authors:  Daniel S Ory; Elizabeth A Ottinger; Nicole Yanjanin Farhat; Kelly A King; Xuntian Jiang; Lisa Weissfeld; Elizabeth Berry-Kravis; Cristin D Davidson; Simona Bianconi; Lee Ann Keener; Ravichandran Rao; Ariane Soldatos; Rohini Sidhu; Kimberly A Walters; Xin Xu; Audrey Thurm; Beth Solomon; William J Pavan; Bernardus N Machielse; Mark Kao; Steven A Silber; John C McKew; Carmen C Brewer; Charles H Vite; Steven U Walkley; Christopher P Austin; Forbes D Porter
Journal:  Lancet       Date:  2017-08-10       Impact factor: 202.731

8.  Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.

Authors:  Cristin D Davidson; Nafeeza F Ali; Matthew C Micsenyi; Gloria Stephney; Sophie Renault; Kostantin Dobrenis; Daniel S Ory; Marie T Vanier; Steven U Walkley
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

Review 9.  Recommendations for the management of tyrosinaemia type 1.

Authors:  Corinne de Laet; Carlo Dionisi-Vici; James V Leonard; Patrick McKiernan; Grant Mitchell; Lidia Monti; Hélène Ogier de Baulny; Guillem Pintos-Morell; Ute Spiekerkötter
Journal:  Orphanet J Rare Dis       Date:  2013-01-11       Impact factor: 4.123

10.  High incidence of unrecognized visceral/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets.

Authors:  Christopher A Wassif; Joanna L Cross; James Iben; Luis Sanchez-Pulido; Antony Cougnoux; Frances M Platt; Daniel S Ory; Chris P Ponting; Joan E Bailey-Wilson; Leslie G Biesecker; Forbes D Porter
Journal:  Genet Med       Date:  2015-03-12       Impact factor: 8.822

View more
  4 in total

1.  Multiomics Analysis of Endocytosis upon HBV Infection and Identification of SCAMP1 as a Novel Host Restriction Factor against HBV Replication.

Authors:  Tanzeel Yousaf; Yuting Sun; Wajeeha Naz; Yang Liu; Jiaqi Xu; Sen Yuan; Kangwei Wu; Min Wang; Jun Wang; Mingxiong Guo; Guihong Sun
Journal:  Int J Mol Sci       Date:  2022-02-17       Impact factor: 5.923

2.  Correlation of age of onset and clinical severity in Niemann-Pick disease type C1 with lysosomal abnormalities and gene expression.

Authors:  Laura L Baxter; Dawn E Watkins-Chow; Nicholas L Johnson; Nicole Y Farhat; Frances M Platt; Ryan K Dale; Forbes D Porter; William J Pavan; Jorge L Rodriguez-Gil
Journal:  Sci Rep       Date:  2022-02-09       Impact factor: 4.996

Review 3.  Mortality in patients with alpha-mannosidosis: a review of patients' data and the literature.

Authors:  Julia B Hennermann; Eva M Raebel; Francesca Donà; Marie-Line Jacquemont; Graziella Cefalo; Andrea Ballabeni; Dag Malm
Journal:  Orphanet J Rare Dis       Date:  2022-07-23       Impact factor: 4.303

Review 4.  Linking Late Endosomal Cholesterol with Cancer Progression and Anticancer Drug Resistance.

Authors:  Mai K L Nguyen; Jaimy Jose; Mohamed Wahba; Marc Bernaus-Esqué; Andrew J Hoy; Carlos Enrich; Carles Rentero; Thomas Grewal
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.